All In Biotech

BLA 125156 · Genentech

Lucentis

Ranibizumab · Injection, Injection · Vascular Endothelial Growth Factor Inhibitor

NovelBreakthrough therapyPriority review

Last checked: Nov 20, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Jun 30, 2006

Approved uses

10

Original approval plus efficacy supplements

Registered trials

538

153 Phase 3, 12 recruiting

FAERS reports

26,326

22,469 serious, 5,093 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 21, 2025.

LUCENTIS is indicated for the treatment of patients with: LUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Myopic Choroidal Neovascularization (mCNV) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Myopic Choroidal Neovascularization (mCNV)

Mechanism: Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF 110 . VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, mCNV, DR, DME and macular edema following RVO. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 15, 2017 Supplement 114 · Efficacy · priority review LabelLetterReview
  • Jan 5, 2017 Supplement 111 · Efficacy · priority review LabelLetter
  • Feb 6, 2015 Supplement 106 · Efficacy · priority review ReviewLetterLabel
  • Nov 25, 2014 Supplement 105 · Efficacy LetterLabel
  • Feb 27, 2014 Supplement 94 · Efficacy LabelLetter
  • Feb 6, 2013 Supplement 81 · Efficacy LabelLetter
  • Aug 10, 2012 Supplement 76 · Efficacy LabelLetter
  • Jun 22, 2010 Supplement 53 · Efficacy · priority review ReviewLabelLetter
  • Apr 23, 2008 Supplement 11 · Efficacy
  • Jun 30, 2006 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
2 products under this application
  • LUCENTIS · RANIBIZUMAB 6MG/ML · Injectable, Injection · Prescription
  • LUCENTIS · RANIBIZUMAB 10MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ranibizumab" as an intervention, any sponsor and status, largest first.

All 538 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death3,801
  • visual acuity reduced2,891
  • off label use1,729
  • visual impairment1,666
  • cerebrovascular accident1,239
  • drug ineffective1,210
  • blindness1,047
  • eye haemorrhage1,047
  • vision blurred1,035
  • no adverse event1,028
  • eye pain961
  • retinal haemorrhage801

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
200652
2007563
2008351
2009691
20101,150
20112,457
20122,382
20132,727
20142,172
20151,268
20161,251
20172,543
20181,575
20191,288
20201,266
20211,039
2022853
2023748
20241,233
2025458
2026258

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lucentis (Ranibizumab)

2024 spending

$2.6M

Beneficiaries

332

1,203 claims

Per beneficiary

$7,924

$34,768.92 per unit

View as table
YearSpending
2020$3,157,221
2021$2,756,595
2022$5,385,256
2023$3,838,736
2024$2,630,671

Part B: Lucentis (Ranibizumab) · HCPCS J2778

2024 spending

$129M

Beneficiaries

33,741

144,995 claims

Per beneficiary

$3,821

2024 ASP limit $158.92 per unit

View as table
YearSpending
2020$1,113,124,781
2021$1,044,929,993
2022$795,501,259
2023$386,040,635
2024$128,919,305

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,047 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.